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Abstract
Background: AMH’s reported stability during periods of hormonal change makes it a practical tool in assessing
ovarian reserve. However, AMH declines with age and age-specific cut-offs remain to be established in women
with proven fertility. This study aims to determine age-specific ranges of AMH in women with proven fertility.
Methods: Two hundred-ten fertile women, aged 18-40 years, were prospectively recruited for AMH measurements
within 14 days after delivery and age stratified into 3 groups (18-30, 31-36 and 37-40 years). Eligibility required
spontaneous conception within a maximal period of six months. Autoimmune diseases, chemotherapy, radiation,
ovarian surgery and polycystic ovary syndrome precluded inclusion.
Results: 95% confidence intervals of AMH declined with advancing female age from 0.9-1.1 to 0.6-0.9 and 0.2-0.4
ng/mL (P < 0.001). AMH levels were not statistically associated with day of blood draw after delivery or pregnancy
characteristics. Neither were they predictive of resumption of menses. They, however, at all ages were lower than
reported in the literature for infertile patients.
Conclusions: Like infertile populations, fertile women demonstrate declining AMH with advancing age. Uniformly
lower levels than in infertile women suggest that AMH levels do not appear as stable under all hormonal
influences as previously reported.
Background
Accurate assessments of ovarian reserve are crucial and
allow for appropriate counselling during women’s repro-
ductive life spans. Anti-Müllerian hormone (AMH) is
increasingly used as diagnostic marker in assessing ovarian
reserve (OR). Indeed, we and others reported improved
accuracy in predicting oocyte yields and pregnancy poten-
tial, compared to baseline follicle stimulating hormone
(b-FSH) [1,2].
Anti-Müllerian hormone is produced in granulosa cells
of small follicles from primary stage on [3,4]. By inhibiting
follicular recruitment [3], AMH exerts regulative functions
on folliculogenesis, and serum concentrations are rela-
tively closely reflective of numbers of antral follicles [5,6].
Antral follicle counts are, however, widely believed to be
directly proportional to a woman’s total follicle pool and,
therefore, reflective of her OR [3,5,7]. AMH’s reported sta-
bility during periods of hormonal change, such as men-
strual cycles and in association with pregnancy, supports
the assumption that AMH may, indeed, be reflective of a
woman’s total follicle pool [8-10]. This AMH characteris-
tic also makes it a more practical clinical tool in compari-
son to other modalities [11].
AMH, however, gradually declines as women age
[12,13]. Among infertile patients, substantially higher
percentages of women at both extremes of AMH values
(i.e., diminished ovarian reserve and polycystic ovary syn-
drome) are observed. Currently available age-specific
normograms were usually established in infertile patient
populations [14]. In an attempt to establish age-specific
values in a fertile cohort, Shebl et al. retrospectively
investigated AMH levels in women undergoing IVF due
to male factor or idiopathic infertility. Their results, how-
ever, clearly demonstrate compromised AMH levels (i.e.
≤1 ng/ml) in 5% of women throughout all ages. They,
therefore, conclude that even young ‘presumbly healthy’
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women undergoing IVF are at risk of diminishing ovarian
reserve. Moreover, no data on pregnancy potential in
those women are given [14]. Age-specific AMH cut-offs,
established in a population with proven fertility, would,
therefore, be useful to accurately diagnose normal age-
specific ovarian reserve or prematurely declining ovarian
reserve, respectively. To determine such age-specific cut-
offs, AMH measurements were initiated in a cohort of
women shortly after delivery after spontaneous concep-
tion within six months of unprotected intercourse.
Methods
Between April 2008 and September 2009, prospective
recruitment of 210 women with proven fertility in three
age strata (n = 70 in each group; Group 1, 18-30 years;
Group 2, 31-36 years; Group 3, 37-40 years) was per-
formed. Recruitment occurred within four and consecutive
blood draw for AMH measurement within 14 days after
delivery at the Department of Obstetrics & Gynecology,
Medical University Vienna, Austria. Follow up telephone
interviews were completed six to 24 months after delivery.
Women were eligible for enrollment if they had con-
ceived spontaneously within six months and were
excluded with a history of infertility, autoimmune disease,
chemo/radiation therapy, ovarian surgery and polycystic
ovary syndrome. All AMH measurements were performed
at the Department of Medical Laboratory Diagnostics,
Medical University Vienna, using the DSL Active MIS/
AMH assay (Beckman Coulter Inc., USA).
After the completion of recruitment, one-hundred-and-
four women were available for follow up telephone inter-
view six to 24 months after delivery and asked about cur-
rent contraceptive methods utilized, duration of breast
feeding and resumption of menses.
In order to establish required sample sizes, differences
in age-related AMH levels were calculated according to
Shebl et al. [14]. To detect a comparable decline of AMH
between the Groups with 80% power and 0.1% level of
significance, a sample size of 62 per group was needed.
We, therefore, decided to recruit 70 women per age
strata.
Baseline characteristics of patients and AMH levels were
compared between the Groups 1 to 3, using analyses of
variance or chi square, as appropriate. Variables that were
not normally distributed were first log transformed, and
are reported as geometric means and 95% confidence inter-
vals (CI). Normally distributed variables were reported as
means ± standard deviation (SD). We used linear regres-
sion to assess effects of baseline characteristics, postpartum
AMH on pregnancy and postpartum factors. A p-value <
0.05 was considered statistically significant. Statistical ana-
lyses were performed using SPSS version 17.0.
Institutional Review Board (IRB) approval was
obtained from the Ethics Committee at the Medical
University Vienna. After recruitment, all patients signed
appropriate informed consents.
Results
Baseline characteristics in the three age strata are shown
in Table 1. Mean age for all study patients was 32.4 ±
5.7 years. Mean postpartum AMH levels were 0.6 ng/ml
(95% CI, 0.5-0.7). AMH determinations were made at an
average of 3.4 ± 2.1 days after delivery. Patients deliv-
ered at a mean gestational age of 38.0 ± 3.2 weeks.
AMH levels were negatively associated with age (p <
0.0001). Average AMH levels by age group were: 0.9 ng/
ml (95% CI, 0.7-1.1) in Group 1, 0.7 ng/ml (95% CI, 0.6-
0.9) in Group 2, and 0.2 ng/ml in Group 3 (95% CI, 0.2-
0.4). There was no difference between age groups in gesta-
tional age at delivery, mode of delivery, fetal gender, birth
weight and intervals between deliveries and AMH draw.
Due to the considerably long time period of up to 24
months between recruitment and follow up, only 104
women were available for a telephone interview. Among
those, menses resumed after mean duration of 3.4 months
(95% CI, 2.6-4.4) in Group 1, after 4.5 months (95% CI,
3.7-5.3) in Group 2, and after 5.3 months (95% CI, 3.9-6.8)
in Group 3. The interval to onset of menses increased sig-
nificantly with increasing age (p < 0.03) and was propor-
tionally delayed with the duration of breast feeding (p <
0.001). Women who completed follow up were evenly dis-
tributed between the age strata.
Using linear regression we found no significant associa-
tion between AMH levels and onset of menses. After con-
structing multiple linear regression models, adjusted for
age, duration of breast feeding and hormonal contracep-
tion usage, there was still no significant effect of AMH
levels on onset of menses.
Discussion
Our results demonstrate gradually declining AMH levels
with age in fertile women, similar to declines reported
in infertile populations [15]. They, however, also show
substantially lower AMH levels postpartum than
reported in infertile patients [10,14]. This, most likely,
reflects a suppressive effect of pregnancy/puerperium on
growing follicle cohorts and, thus, AMH. Though
patient age and duration of breast feedings significantly
influenced intervals to resumption of menses, AMH
levels did not.
This study investigated only women with proven ferti-
lity. It, therefore, appears unlikely that the observed,
apparently suppressed, AMH levels postpartum reflect
their actual total follicle pool. The substantially reduced
AMH concentrations postpartum may, therefore, mirror
lower folliculogenesis after delivery. These assumptions
are supported by the delay of menopause in multiparous
women [16,17].
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Recent findings of Nelson et al. are in accordance with
the assumption of a suppressive effect of hormonal
changes on AMH levels: They reported declining AMH
levels during second and third trimesters of pregnancy
[18], contradicting prior observations that claimed AMH
to be stable during pregnancy and puerperium [19,20].
Also contrary to prior reports [21], AMH may also be
suppressed with oral contraceptives [22]. Van den Berg
et al. recently reported that AMH on day seven of con-
traception free intervals does not correspond to AMH
values in subsequent natural cycles. They reported not
only increasing AMH levels immediately after cessation
of contraception, but even higher levels after two
months from cessation [22].
Data from women with polycystic ovary syndrome
(PCOS) after ovarian drilling further support the point:
Shebl et al. report decreased AMH levels shortly after
ovarian drilling, when compared to pre-surgery levels.
AMH, however, returned to approximately original
levels within six months from surgery [23].
All of these data raise questions as to what extent, and
under which conditions, AMH is reflective of the total
follicle pool. It, indeed, appears possible that AMH pri-
marily reflects growing follicles (i.e. an actively maturing
follicle cohort), but not - or not under all circumstances -
the complete follicle pool. Further studies are, therefore,
warranted to evaluate factors that might possibly inter-
fere with AMH secretion or rather under which condi-
tions AMH concentrations can be utilized to assess
ovarian reserve.
This study, as one would expect, also demonstrates a
significant decline of AMH levels with age in fertile
women. Fertile women, further, show a significant correla-
tion between age and resumption of menses - the older a
woman is at the time of delivery the longer it takes to
resume menses. Latter correlation could reflect declines in
ovarian reserve with advancing female age, and one, there-
fore, would expect a comparable association between post-
partum AMH levels and resumption of menses (corrected
for breast feeding and hormonal contraceptive usage), if
AMH, indeed, was reflective of total ovarian follicle pools.
Our data, however, clearly failed to demonstrate such an
association. Though data on resumption of menses were
not available for the whole cohort of 210 women, this lack
of association was seen in all three age groups.
Conclusions
Like infertile populations, fertile women demonstrate
declining AMH with advancing age. Uniformly lower
levels than in infertile women suggest that AMH levels
do not appear as stable under all hormonal influences as
previously reported.
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